Why Generic Glaucoma Surgery Campaigns Miss MIGS Patients

The MIGS category does not search like other glaucoma topics. A patient who has been told they need glaucoma surgery, or who has been offered a MIGS combination at the time of cataract evaluation, leaves the consultation with a specific device name written on a referral note. The next searches that patient runs are for the device, “iStent recovery”, “Hydrus reviews”, “XEN gel stent before and after”, not for the procedure category. Patients researching alternatives to drops behave the same way; the educational content that converts them mentions specific devices because that is how the manufacturers and the medical literature have framed the category.

Practices that run a single “glaucoma surgery” campaign with broad-match keywords capture the trickle of patients searching for the procedure category and miss the much larger pool searching for specific devices. The miss is invisible from the search-terms report alone, because broad match does sometimes pull device-named queries, but impression share on those auctions is low and CTR is poor because the ad copy describes a generic procedure. The device-specific traffic accumulates at competitor practices, manufacturer patient-finder pages, and academic centers that built device-specific content.

How MIGS Patient Searchers Split Into Two Segments

MIGS patient searchers fall into two segments with very different content needs. The first is existing glaucoma patients researching alternatives to drops. These patients have been on topical therapy for months or years, are frustrated with adherence (multi-drop nonadherence runs around 50 percent in the published literature), and are searching for treatments that could reduce or eliminate the drop burden. Their queries include “alternatives to glaucoma drops”, “glaucoma surgery without drops”, “SLT vs MIGS”, “Durysta sustained release”. The conversion path is educational; they need content explaining what the alternatives are, who is a candidate, and what the trade-offs are.

The second segment is patients referred specifically for MIGS evaluation, usually after a combined cataract-glaucoma surgery discussion with a comprehensive ophthalmologist. These patients arrive with a procedure name and a manufacturer hand-out, and their queries are device-specific and procedure-specific, “iStent inject W procedure”, “Hydrus Microstent surgeon near me”, “OMNI canaloplasty recovery time”. The conversion path is procedural; they need surgeon experience, FDA-cleared indication detail, and scheduling information.

The same landing page does not serve both segments well. The educational page that wins the drop-frustrated patient is too soft for the post-referral patient who already knows the device name and wants procedural specifics. The procedural page that converts the post-referral patient is intimidating for the drop-frustrated patient who is still in the alternatives-research stage. The right structure is parallel landing pages with cross-links, each tuned to its segment’s intent. The companion glaucoma HCP referral piece covers the B2B side of the same content architecture.

The Demand and Conversion-Rate Picture for MIGS

No published CPC data is specific to MIGS queries (the category is too narrow for most benchmark sources). Device-specific queries typically run lower CPC than “glaucoma surgery” generics because the auction density on device-named keywords is lower; the practice is competing primarily with manufacturer-funded patient-finder ads rather than with the full spread of glaucoma surgical practices. Conversion rates on matched MIGS device pages often run 20 to 35 percent, well above generic glaucoma-surgery page conversion rates, because the searcher’s intent is post-diagnosis and the matched landing page meets that intent directly.

The category itself is growing 15 to 20 percent annually, outpacing traditional glaucoma surgery. The growth is driven by the combined cataract-MIGS economics (most MIGS is Medicare-covered when bundled with cataract, with patient out-of-pocket usually under $500), by surgeon adoption of newer devices, and by the steady flow of patients dissatisfied with topical therapy looking for alternatives. A practice that has built device-specific landing pages and ad groups captures a growing share of growing demand; a practice that has not is gradually ceding share to competitors who did. The companion PPC benchmarks piece covers the broader eye care baselines.

Five Red Flags in MIGS Marketing Setup

The following patterns indicate the practice is missing the MIGS opportunity. First, no device-specific ad groups or landing pages. The account runs a single glaucoma-surgery campaign and a single landing page covering everything, which means the device-named query lands on a generic page that does not match the intent. The bounce rate is high and the conversion rate is poor, both visible in analytics if anyone is looking. Second, all MIGS devices are covered on one generic MIGS page rather than on device-specific pages. The page mentions iStent, Hydrus, XEN, and OMNI in a single list, which serves the awareness-stage reader but converts nobody who arrived with a specific device name in mind.

Third, surgeon experience with specific devices is not surfaced. The patient who searched “iStent surgeon near me” wants to know that the surgeon has done a meaningful number of iStent procedures, not the generic glaucoma surgical case volume. Without case-volume data per device, the page reads as a brochure rather than as a credible procedural offering. Fourth, no “MIGS alternative to drops” content for the drop-frustrated patient. The educational segment of the funnel is missing entirely, which means the practice captures only the post-referral traffic and not the much larger pool of patients researching alternatives.

Fifth, FDA-cleared indications are mis-stated in copy. Each device has a specific FDA-cleared indication (for example, iStent is indicated for mild to moderate open-angle glaucoma in adult cataract patients), and copy that stretches the indication is a regulatory risk. The compliance review on MIGS landing pages should match each device’s labeling exactly. The companion server-side tagging piece covers the upstream PHI-handling discipline that pairs with device-specific page architecture.

The Concrete MIGS Campaign Build

Build device-specific landing pages for each MIGS device the practice offers. Each page covers the device, surgeon case volume on that specific device, FDA-cleared indications stated precisely (work from the manufacturer’s regulatory team for approved language), the ideal patient profile, the typical outcome trajectory, and recovery expectations. Cross-link between device pages with comparison content (“iStent vs Hydrus”) and cross-link to the alternatives-to-drops educational content for the drop-frustrated segment.

Structure ad groups by device. Each device gets its own ad group with exact and phrase match on the device name and adjacent variants, ad copy that mentions the device by name, and the landing page that matches. The campaign-level negative list excludes manufacturer brand searches that should not flow to the practice (some device manufacturers prohibit competitor surgeons from bidding on their brand) and excludes generic glaucoma-drop queries that belong in different campaigns.

Separate the referral-patient landing track from the self-researching-patient landing track. The referral track gets prominent surgeon information, scheduling, and procedural specifics. The research track gets educational content with a soft conversion (newsletter, guide download) before the harder conversion of consult booking. Measure each device’s contribution to total MIGS volume monthly; the data informs which devices are worth expanded budget and which are not driving meaningful procedural traffic. The companion AI Max HIPAA piece covers the targeting governance that pairs with the campaign-level structure.

Specialty Vision’s Take on MIGS Marketing in 2026

Our view, MIGS is the clearest growth segment in glaucoma marketing in 2026. The category is growing 15 to 20 percent annually, the patient research is device-specific, and practices with device-level campaigns and landing pages capture a growing share of growing demand. The opportunity compounds: the optometrist who sees a practice’s iStent case-volume content is more likely to refer the next iStent candidate.

Most generic glaucoma-surgery campaigns leave this growth on the table because they treat MIGS as a sub-category rather than the device-named market it is. The fix requires a page per device, an ad group per device, and FDA-cleared-indication language. Manufacturers provide approved copy on request, and a small documented review process keeps the language defensible.

Practices that build device-specific campaigns capture both patient-research traffic and the referring-OD education opportunity. For broader audit context, see our 2026 PPC audit playbook.